Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitor and immune checkpoint inhibitor have synergism efficacy in gallbladder cancer.

Genes and immunity - 1 Aug 2024

Chen Yu, Fan Xudong, Lu Ruohuang, Zeng Shan, Gan Pingping

Abstract excerpt

Gallbladder cancer (GBC) is an aggressive cancer with poor prognosis. PARP inhibitors (PARPi) target PARP enzymes and have shown efficacy in patients with breast cancer gene (BRCA) mutations. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has transformed cancer treatment. However, the combined impact of PARPi and ICIs in GBC remains unclear. We present a groundbreaking case of a GBC patient with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gallbladder Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Tumor Microenvironment

Source

Identifiers

PMID: 38866965
DOI: 10.1038/s41435-024-00280-9

Genes

BRCA2
BRCA1
CEACAM1
PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitor and immune checkpoint inhibitor have synergism efficacy in gallbladder cancer.PMID 38866965Read ↗

PARP inhibitor and immune checkpoint inhibitor may have synergism efficacy in gallbladder cancerSemantic proximity Read ↗

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.Semantic proximity Read ↗

Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targetsSemantic proximity Read ↗

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune SignaturesSemantic proximity Read ↗

Genomic and molecular landscape of gallbladder cancer elucidating pathogenic mechanisms novel therapeutic targets and clinical implications.Semantic proximity Read ↗

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?Semantic proximity Read ↗

DNA Checkpoint Gene Mutation as a Biomarker for Immune Checkpoint Inhibitor Therapy in Advanced Biliary Tract Cancer.Semantic proximity Read ↗

Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patientsSemantic proximity Read ↗

Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives.Semantic proximity Read ↗

CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment.Semantic proximity Read ↗

The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancerSemantic proximity Read ↗

Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.